Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Trial details
- Registry ID
- NCT02768363
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as AdV-tk; CAN-2409
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363 | CADL | Phase 2 | Active not recruiting | 2024-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |